Skip to content
Screener

Nektar Therapeutics NKTR Total Current Liabilities

Total Current Liabilities at other companies

Amgen logo
AmgenAMGN
$25.5B+24.5%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$5.53B+50.8%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$67.95M+38.1%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$32.95M0.0%
Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
$14.58M+35.4%
CTO
Citius Oncology, Inc.CTOR
$58.81M+18.2%

Other financials

Income statement

See full
Revenue$10.9M+3.8%
Gross profit$21.8M+2.9%
Operating income-$39.1M+12.3%
Net income-$44.9M+11.7%
EPS (diluted)-$1.82+49.7%

Balance sheet

See full
Cash & equivalents$5.7M-20.0%
Total debt$83.2M-17.1%
Total equity$576.2M+4,094%
Total assets$763.3M+198%

Cash flow

See full
Operating cash flow-$44.3M+9.7%
CapEx$18.0K+800%
Free cash flow-$44.3M+9.7%

Valuation

See full
Market cap$2.48B+539%
Enterprise value$2.56B+435%
P/S44.6×+39.4×

Profitability

See full
Gross margin100%+31.2pp
Operating margin-242%
Net margin-284.2%+937pp
FCF margin-366.6%+1,421pp

Returns & leverage

See full
Return on equity-53.6%-22.6pp
Debt / equity0.1×-7.2×
Current ratio10.2×+7.0×

Where this comes from

Reported directly by Nektar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.

The source filing: Nektar Therapeutics’s 10-Q, filed May 8, 2026.

Filed
May 7, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-212596
Line itemMarch 31, 2026December 31, 2025
Accounts payable (including $504 and $137 as of March 31, 2026 and December 31, 2025, respectively, to a related party)$10,026$10,770
Accrued expenses (including $1,148 and $994 as of March 31, 2026 and December 31, 2025, respectively, to a related party)25,15122,271
Operating lease liabilities, current portion22,53120,495
Total current liabilities57,70853,536
Operating lease liabilities, less current portion60,63165,256
Liabilities related to the sales of future royalties, net60,27063,157
Other long-term liabilities8,4468,625
Total liabilities187,055190,574

Item 1. Condensed Consolidated Financial Statements—Unaudited:

FAQ

What is Nektar Therapeutics's total current liabilities?
Nektar Therapeutics (NKTR) reported total current liabilities of $57.71M in Q1 2026.
How has Nektar Therapeutics's total current liabilities changed year-over-year?
Nektar Therapeutics's total current liabilities decreased by 18.6% year-over-year, from $70.93M to $57.71M.
What is the long-term trend for Nektar Therapeutics's total current liabilities?
Over 5 years (2020 to 2025), Nektar Therapeutics's total current liabilities has grown at a -14.3% compound annual growth rate (CAGR), from $115.78M to $53.54M.
What does total current liabilities mean?
The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.

Ask your AI about Nektar Therapeutics's total current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude